Clinical Infectious Diseases · 17 Nov 2026
Trial Endpoints for Endemic Mycoses: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and European Confederation of Medical Mycology
George R Thompsonh-index 20, Neil M Ampel, Nathan C Bahr, Tom Chiller, Claudia E Frola, Nelesh P Govender, Thomas J Walsh, Emmanuel Roilides, Marisa H Miceli, Alessandro C Pasqualotto, Rob Purdie, Flavio Queiroz-Telles, Andrej Spec, Rosanne Sprute, Thuy Le, Ana Alastruey-Izquierdoh-index 50
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- Crossref1
- OpenCitations0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Background Endemic mycoses, caused by Blastomyces, Coccidioides, Emergomyces, Histoplasma, Paracoccidioides, Sporothrix, and Talaromyces marneffei, represent an important global health challenge. Expanding endemic regions, climatic change, improved diagnostics, increased disease awareness, and an increasing at-risk population have contributed to rising case numbers. These infections affect both immunocompetent and immunocompromised hosts and exhibit marked clinical heterogeneity. Current treatment response guidance, established by the Mycoses Study Group and the European Organization for Research and Treatment of Cancer in 2008, are primarily tailored for invasive yeast and mold infections and are inadequate for endemic mycoses due to their complexity and heterogeneity. Methods An international, multidisciplinary expert panel convened through the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology to develop consensus guidance for treatment response assessment in endemic mycoses. The process included a structured literature review, expert discussion, regulatory consultation, patient input, and public comment, culminating in consensus-based response criteria. Results The proposed guidance response criteria encompass clinical, mycologic, and radiologic assessments. Conclusions The new criteria aim to improve the accuracy and standardize the assessment of treatment response, enabling comparison and pooling results across clinical trials while addressing the unique challenges posed by these diverse pathogens.
What the data shows
- Crossref counts 1 citations, the most of the databases. The others count 0.
- Ana Alastruey-Izquierdo has the highest h-index among the authors (50).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (56)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 36 more references
A free account opens the rest of the citing papers and references on every paper’s page.